Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature

  • Tina Wanting Zhang
  • , Jonatan Snir
  • , R. Gabriel Boldt
  • , George B. Rodrigues
  • , Alexander V. Louie
  • , Stewart Gaede
  • , Ronald C. McGarry
  • , James J. Urbanic
  • , Megan E. Daly
  • , David A. Palma

Producción científica: Articlerevisión exhaustiva

62 Citas (Scopus)

Resumen

Purpose: Some recent studies have suggested a relationship between cardiac dose and mortality in non-small cell lung cancer (NSCLC), but others have reported conflicting data. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between cardiac dose and mortality in these patients. Methods and Materials: A systematic review of MEDLINE (PubMed) and Embase databases (inception to January 2018) was performed according to PRISMA guidelines. Studies that evaluated cardiac dosimetric factors in patients with NSCLC and included outcomes of cardiac events, cardiac mortality, and/or overall survival were identified. Results: From 5614 patients across 22 studies, a total of 214 cardiac dosimetric parameters (94 unique) were assessed as possible predictors of cardiac toxicity or death. Assessed predictors included general (eg, mean heart dose [MHD]), threshold-based (eg, heart V5), and anatomic-based (eg, atria, ventricles) dosimetric factors. The most commonly analyzed parameters were MHD, heart V5, and V30. Most studies did not make corrections for multiplicity of testing. For overall survival, V5 was found to be significant on multivariable analysis (MVA) in 1 of 11 studies and V30 in 2 of 12 studies; MHD was not significant in any of 8 studies. For cardiac events, V5 was found to be significant on multivariable analysis in 1 of 2 studies, V30 in 1 of 3 studies, and MHD in 2 of 4 studies. A meta-analysis of the data could not be performed because most negative studies did not report effect estimates. Conclusions: Consistent heart dose-volume parameters associated with overall survival of patients with NSCLC were not identified. Multiplicity of testing is a major issue and likely inflates the overall risk of type I errors in the literature. Future studies should specify predictors a priori, correct for multiplicity of testing, and report effect estimates for nonsignificant variables.

Idioma originalEnglish
Páginas (desde-hasta)582-589
Número de páginas8
PublicaciónInternational Journal of Radiation Oncology Biology Physics
Volumen104
N.º3
DOI
EstadoPublished - jul 1 2019

Nota bibliográfica

Publisher Copyright:
© 2019 Elsevier Inc.

Financiación

Dr David Palma is supported by a Clinician Scientist Grant from the Ontario Institute for Cancer Research.Conflict of interest: A.V.L. has received honoraria from Varian Medical Systems Inc and has received consultant fees from AstraZeneca. M.E.D. has received research funding from EMD Serono. Dr David Palma is supported by a Clinician Scientist Grant from the Ontario Institute for Cancer Research.Conflict of interest: A.V.L. has received honoraria from Varian Medical Systems Inc and has received consultant fees from AstraZeneca. M.E.D. has received research funding from EMD Serono. Dr David Palma is supported by a Clinician Scientist Grant from the Ontario Institute for Cancer Research. Conflict of interest: A.V.L. has received honoraria from Varian Medical Systems Inc and has received consultant fees from AstraZeneca. M.E.D. has received research funding from EMD Serono. The authors would like to acknowledge Dr J. Bradley, Dr J. Greenberger, Dr S. Chun, Dr C.B. Han, Dr C. Robinson, Dr B. Dess, Dr T. Schytte, and Dr K. Wang for their assistance with this publication and provision of hazard ratios from their original publications. Dr David Palma is supported by a Clinician Scientist Grant from the Ontario Institute for Cancer Research. Conflict of interest: A.V.L. has received honoraria from Varian Medical Systems Inc and has received consultant fees from AstraZeneca. M.E.D. has received research funding from EMD Serono.

Financiadores
Ontario Institute for Cancer Research.Conflict
AstraZeneca
EMD Serono Research Institute
Ontario Institute for Cancer Research

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Radiation
    • Oncology
    • Radiology Nuclear Medicine and imaging
    • Cancer Research

    Huella

    Profundice en los temas de investigación de 'Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature'. En conjunto forman una huella única.

    Citar esto